A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory ()

  • Non Hodgkin ()
  • Follicular Lymphoma
  • Relapsed or Refractory Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma (DLBCL)